Cargando…

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial

BACKGROUND: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for who...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Shiro, Katakami, Nobuyuki, Masago, Katsuhiro, Yoshioka, Hiroshige, Tomii, Keisuke, Kaneda, Toshihiko, Hirabayashi, Masataka, Kunimasa, Kei, Morizane, Toshio, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404930/
https://www.ncbi.nlm.nih.gov/pubmed/22613958
http://dx.doi.org/10.1186/1471-2407-12-185
_version_ 1782239044595351552
author Fujita, Shiro
Katakami, Nobuyuki
Masago, Katsuhiro
Yoshioka, Hiroshige
Tomii, Keisuke
Kaneda, Toshihiko
Hirabayashi, Masataka
Kunimasa, Kei
Morizane, Toshio
Mio, Tadashi
author_facet Fujita, Shiro
Katakami, Nobuyuki
Masago, Katsuhiro
Yoshioka, Hiroshige
Tomii, Keisuke
Kaneda, Toshihiko
Hirabayashi, Masataka
Kunimasa, Kei
Morizane, Toshio
Mio, Tadashi
author_sort Fujita, Shiro
collection PubMed
description BACKGROUND: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized based on EGFR mutation status. METHODS: We screened 57 chemotherapy-naïve patients with histologically or cytologically confirmed NSCLC, stage IIIB or IV, aged 70 years or older, and with an Eastern Cooperative Oncology Group performance status 0 or 1, for EGFR exon 19 codon 746–750 deletion and exon 21 L858R mutation. Twenty-two patients with EGFR mutations received gefitinib; 32 patients without mutations received vinorelbine or gemcitabine. The primary endpoint was the response rate. RESULTS: The response rate was 45.5% (95% confidence interval [CI]: 24.4%, 67.8%) in patients with EGFR mutations and 18.8% (95% CI: 7.2%, 36.4%) in patients without EGFR mutations. The median overall survival was 27.9 months (95%CI: 24.4 months, undeterminable months) in patients with EGFR mutations and 14.9 months (95%CI: 11.0 months, 22.4 months) in patients without EGFR mutations. In the gefitinib group, grade 3/4 hepatic dysfunction and dermatitis occurred in 23% and 5% of patients, respectively. In patients treated with vinorelbine or gemcitabine, the most common grade 3 or 4 adverse events were neutropenia (47%; four had febrile neutropenia), anemia (13%), and anorexia (9%). No treatment-related deaths occurred. CONCLUSIONS: Treatment customization based on EGFR mutation status deserves consideration, particularly for elderly patients who often cannot receive second-line chemotherapy due to poor organ function or comorbidities. TRIAL REGISTRATION: This trial is registered at University hospital Medical Information Network-clinical trial registration (http://www.umin.ac.jp/ctr/index/htm) with the registration identification number C000000436.
format Online
Article
Text
id pubmed-3404930
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34049302012-07-26 Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial Fujita, Shiro Katakami, Nobuyuki Masago, Katsuhiro Yoshioka, Hiroshige Tomii, Keisuke Kaneda, Toshihiko Hirabayashi, Masataka Kunimasa, Kei Morizane, Toshio Mio, Tadashi BMC Cancer Research Article BACKGROUND: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized based on EGFR mutation status. METHODS: We screened 57 chemotherapy-naïve patients with histologically or cytologically confirmed NSCLC, stage IIIB or IV, aged 70 years or older, and with an Eastern Cooperative Oncology Group performance status 0 or 1, for EGFR exon 19 codon 746–750 deletion and exon 21 L858R mutation. Twenty-two patients with EGFR mutations received gefitinib; 32 patients without mutations received vinorelbine or gemcitabine. The primary endpoint was the response rate. RESULTS: The response rate was 45.5% (95% confidence interval [CI]: 24.4%, 67.8%) in patients with EGFR mutations and 18.8% (95% CI: 7.2%, 36.4%) in patients without EGFR mutations. The median overall survival was 27.9 months (95%CI: 24.4 months, undeterminable months) in patients with EGFR mutations and 14.9 months (95%CI: 11.0 months, 22.4 months) in patients without EGFR mutations. In the gefitinib group, grade 3/4 hepatic dysfunction and dermatitis occurred in 23% and 5% of patients, respectively. In patients treated with vinorelbine or gemcitabine, the most common grade 3 or 4 adverse events were neutropenia (47%; four had febrile neutropenia), anemia (13%), and anorexia (9%). No treatment-related deaths occurred. CONCLUSIONS: Treatment customization based on EGFR mutation status deserves consideration, particularly for elderly patients who often cannot receive second-line chemotherapy due to poor organ function or comorbidities. TRIAL REGISTRATION: This trial is registered at University hospital Medical Information Network-clinical trial registration (http://www.umin.ac.jp/ctr/index/htm) with the registration identification number C000000436. BioMed Central 2012-05-21 /pmc/articles/PMC3404930/ /pubmed/22613958 http://dx.doi.org/10.1186/1471-2407-12-185 Text en Copyright ©2012 Fujita et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fujita, Shiro
Katakami, Nobuyuki
Masago, Katsuhiro
Yoshioka, Hiroshige
Tomii, Keisuke
Kaneda, Toshihiko
Hirabayashi, Masataka
Kunimasa, Kei
Morizane, Toshio
Mio, Tadashi
Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
title Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
title_full Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
title_fullStr Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
title_full_unstemmed Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
title_short Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
title_sort customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase ii trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404930/
https://www.ncbi.nlm.nih.gov/pubmed/22613958
http://dx.doi.org/10.1186/1471-2407-12-185
work_keys_str_mv AT fujitashiro customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT katakaminobuyuki customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT masagokatsuhiro customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT yoshiokahiroshige customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT tomiikeisuke customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT kanedatoshihiko customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT hirabayashimasataka customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT kunimasakei customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT morizanetoshio customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial
AT miotadashi customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial